4 Stocks That Wall Street Hates This Week

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
4 Stocks That Wall Street Hates This Week

© Joe Raedle / Getty Images

Wall Street analysts are constantly releasing and updating reports on stocks across their respective coverage universes. These calls, whether positive or negative, play into the overall perception of the stock and can easily influence investors, especially if the broker making the call is a big name like Goldman Sachs.

While these analysts may differ in terms of their approach or analytics, their bottom line tends to this: a stock is going up, going down or just keeping pace with the market.

Every day, 24/7 Wall St. reviews top analysts’ research from the major brokerage firms and investment houses, and we compile the best and most prominent upgrades and downgrades. It is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.

Here are a few stocks that we think Wall Street hated the most in this past week.

[nativounit]

Exelon Corp. (NASDAQ: EXC | EXC Price Prediction): Scotiabank downgraded the stock to Sector Perform from Outperform and cut the price target to $44 from $55. The 52-week trading range is $27.35 to $44.02, and shares have a consensus target of $50.78. The stock traded Friday morning at $42.50 a share.

Stanley Black & Decker Inc. (NYSE: SWK): Citigroup downgraded the shares to Sell from Buy and cut the price target to $145 from $215. The consensus target price is $211.44, and the stock traded on Friday at $165.50. This implies more than 12% downside from Citigroup’s target price.

Big Lots Inc. (NYSE: BIG): JPMorgan lowered its Neutral rating to Underweight and slashed the $54 target price to $31. The consensus target is $44.44, and the stock recently traded at $37.50. This implies more than 17% downside from JPMorgan’s target price.

Incyte Corp. (NASDAQ: INCY): SVB Leerink’s downgrade to Underperform from Market Perform included a price target cut from $60 to $56. The 52-week trading range is $61.91 to $88.26, and shares traded at $67.60 on Friday. This implies about 17% downside from the analyst’s target.

[recirclink id=1046001][wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618